The National Alzheimer's Coordinating Center (NACC) (www.alz.washington.edu) was begun in 1999 to facilitate collaborative research among the Alzheimer's Disease Centers funded independently by NIA as the Alzheimer's Disease Centers Program since 1984. During the initial phase of its development, NACC collected a """"""""minimal data set (MDS)"""""""" of clinical data on the subjects who had been enrolled at ADCs since 1984. Then in 2005, through close collaboration with NIA and the ADC Clinical Task Force, a detailed clinical evaluation and data-collection system was implemented called the Uniform Data Set (UDS);its protocol required annual follow-up examinations to monitor change over time in the patients and normal controls. About 66,000 persons were included in the MDS and 29,000 so far in the UDS (some with up to seven annual follow-up visits). From the MDS and UDS there is a total of about 13,000 persons who have died and had an autopsy to determine pathologic basis for their condition. All of these data have been collected by NACC and are housed in the NACC database. The data are freely available to researchers on request. There have been 306 publications within the 2009 - 14 grant cycle. NACC develops the clinical forms and documentation for all the data collection, working closely with the ADC CTF and with each Center. We have become an integral part of the ADC Program, not only to collect enrollment data and monitor ADC progress, but also to provide a large and unparalleled research database to the scientific community. We are now applying to continue NACC's efforts for another five years. During that time we will: a.) Maintain and increase the research capability of the NACC database by adding refined diagnostic data and, as it is approved by the CTF and NIA, disease specific modules as well as imaging and other biomarker data. We have maintained high data quality standards over the years and will continue to do so, through a detailed system of database error checks and communication with the Centers. b.) Facilitate and conduct research using NACC data by providing data and consultation to investigators;providing competitive peer-reviewed funding to several projects per year;and conducting internal applied and theoretical research. c.) Collaborate with national and international efforts on AD and other dementias, such as the Alzheimer's Disease Genetics Consortium, and make the UDS and other instruments available to non-ADC researchers anywhere in the world. d.) Continue the NIA-required administrative coordination of ADC meetings and ADC communications.

Public Health Relevance

Alzheimer's disease is an important public health problem, one that is devastating to those who suffer from it, to their families, and to the communities in which they live. NACC has since 1999 served as the data coordinating center for the NIA Alzheimer's Disease Centers Program nationwide. Standardized clinical and neuropathological data are received from approximately 30 Centers, and these data are made freely available to researchers everywhere, in order that they may form hypotheses and test research questions that will advance our understanding of Alzheimer's disease and related disorders

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01AG016976-16
Application #
8759139
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5 (M4))
Program Officer
Phelps, Creighton H
Project Start
1999-07-01
Project End
2019-06-30
Budget Start
2014-08-15
Budget End
2015-06-30
Support Year
16
Fiscal Year
2014
Total Cost
$4,099,816
Indirect Cost
$706,917
Name
University of Washington
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Kunutsor, Setor K; Laukkanen, Jari A; Burgess, Stephen (2018) Genetically elevated gamma-glutamyltransferase and Alzheimer's disease. Exp Gerontol 106:61-66
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
Khachaturian, Ara S; Hayden, Kathleen M; Mielke, Michelle M et al. (2018) Future prospects and challenges for Alzheimer's disease drug development in the era of the NIA-AA Research Framework. Alzheimers Dement 14:532-534
Davis, Matthew; O Connell, Thomas; Johnson, Scott et al. (2018) Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia. Curr Alzheimer Res 15:777-788
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Scelsi, Marzia A; Khan, Raiyan R; Lorenzi, Marco et al. (2018) Genetic study of multimodal imaging Alzheimer's disease progression score implicates novel loci. Brain 141:2167-2180
Nordestgaard, Liv Tybjærg; Tybjærg-Hansen, Anne; Rasmussen, Katrine Laura et al. (2018) Genetic variation in clusterin and risk of dementia and ischemic vascular disease in the general population: cohort studies and meta-analyses of 362,338 individuals. BMC Med 16:39
Kaur, Antarpreet; Edland, Steven D; Peavy, Guerry M (2018) The MoCA-Memory Index Score: An Efficient Alternative to Paragraph Recall for the Detection of Amnestic Mild Cognitive Impairment. Alzheimer Dis Assoc Disord 32:120-124
Cleary, Ekaterina Galkina; Cifuentes, Manuel; Grinstein, Georges et al. (2018) Association of Low-Level Ozone with Cognitive Decline in Older Adults. J Alzheimers Dis 61:67-78
Brenowitz, Willa D; Han, Fang; Kukull, Walter A et al. (2018) Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. Neurobiol Aging 62:64-71

Showing the most recent 10 out of 552 publications